Patient advocacy organizations and FDA drug approval: lessons from Aduhelm
Patient advocacy organizations need to shift their paradigm from "any drug at any cost" to "the best drug at the right cost." More
Patient advocacy organizations need to shift their paradigm from "any drug at any cost" to "the best drug at the right cost." More
Medical debt and collection actions further perpetuate racial inequities by limiting economic opportunities and further contributing to the wealth divide. More
Disinfecting surfaces does little to curb Covid's spread. So why are two big health nonprofits working with Clorox? More
This Viewpoint discusses the US Food and Drug Administration’s accelerated approval pathway and proposes the need for reforms as well as the timely completion of postapproval trials. More
The value of the nonprofit tax exemption is worth tens of billions to hospitals. But what are we getting back in exchange for this hefty tax break? Watch the launch video for a discussion of community benefit standards, hospital billing practices, and fair share spending with health policy experts. More
Though all nonprofit hospitals enjoy big tax breaks, many fail to make commensurate investments in community health, according to a new analysis from the Lown Institute. The Institute today released Community Benefit findings from its 2021 Hospitals Index, that show nonprofit hospitals collectively failed to invest nearly $17 billion in their communities. More
This cross-sectional study uses data from the Centers for Medicare & Medicaid Services to assess whether higher-performing hospitals are more likely to advertise their services directly to consumers. More
Since January, hospitals were supposed to be disclosing true prices for their services, as a way to empower patients to shop around. Turns out, compliance is spotty and the data can be hard to find. More
The Biden administration released the first part of regulations to implement a law that bans surprise medical bills, outlining what types of charges will be outlawed starting in 2022. More
Although most well-known patient organizations have important missions and provide invaluable services to patients, many appear unable or unwilling to take positions on consumer issues such as lowering prescription drug prices that might anger their drug corporation funders.
Plans like United Healthcare say it’s necessary to contain health care costs. Experts say it’s the wrong approach. More
How New Hospital Transparency Regulations Fall Short More
Consumers may think they’re safer or more “natural” than pharmaceuticals, but multiple studies show they are sometimes adulterated with medicines and unknown additives. More
When Aduhelm’s prospects appeared dead, Biogen mounted a secret campaign to resurrect the drug and convince the FDA to approve it. More
Nearly 70% of all U.S. physicians are now employed by hospitals or corporations. More
Two new studies analyzing hospital price transparency find that fewer than 25% of hospitals are complying with the new CMS rule. More
A Q&A with physician and former FDA advisor Aaron Kesselheim on why he resigned to protest the approval of a new Alzheimer’s drug — and the reforms necessary to prevent it from happening again. More
The 1,000 new residency slots funded by the American Rescue Plan should go first to hospitals in rural, underserved, and tribal areas. More